Premium
Analysis of malignant melanoma risk and outcomes in solid organ transplant recipients: Assessment of transplant candidacy and the potential role of checkpoint inhibitors
Author(s) -
Zwald Fiona,
Carvajal Richard D.,
Walker John,
Sawinski Deirdre,
AlAdra David
Publication year - 2021
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.14264
Subject(s) - medicine , candidacy , melanoma , transplantation , organ transplantation , population , oncology , intensive care medicine , cancer research , environmental health , politics , political science , law
Abstract Malignant melanoma (MM) causes tremendous morbidity and mortality in the solid organ transplant population and may arise in three different clinical scenarios: (1) pretransplant melanoma; (2) de novo melanoma post transplantation and (3) donor‐derived melanoma. This manuscript primarily addresses the first two scenarios with respect to the evaluation and management of pretransplant MM, consideration of transplant candidacy and the occurrence and management of de novo MM post transplantation. The authors outline current evidence describing risks associated with pre‐transplant melanoma to support recently established expert opinion for transplant candidacy.